GR852895B - - Google Patents

Info

Publication number
GR852895B
GR852895B GR852895A GR850102895A GR852895B GR 852895 B GR852895 B GR 852895B GR 852895 A GR852895 A GR 852895A GR 850102895 A GR850102895 A GR 850102895A GR 852895 B GR852895 B GR 852895B
Authority
GR
Greece
Prior art keywords
6alkyl
hydrogen
3alkyl
benzyloxy
phenoxy
Prior art date
Application number
GR852895A
Other languages
English (en)
Inventor
Faizulla G Kathawala
Sompong Wattanasin
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of GR852895B publication Critical patent/GR852895B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
    • C07C17/263—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions
    • C07C17/2632—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions involving an organo-magnesium compound, e.g. Grignard synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/24—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C07C47/57—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
GR852895A 1984-12-04 1985-12-02 GR852895B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67791784A 1984-12-04 1984-12-04

Publications (1)

Publication Number Publication Date
GR852895B true GR852895B (el) 1986-04-01

Family

ID=24720627

Family Applications (1)

Application Number Title Priority Date Filing Date
GR852895A GR852895B (el) 1984-12-04 1985-12-02

Country Status (19)

Country Link
EP (1) EP0216785B1 (el)
JP (1) JPS62501009A (el)
KR (1) KR910003427B1 (el)
AT (1) ATE60571T1 (el)
AU (1) AU599580B2 (el)
DE (1) DE3581638D1 (el)
DK (1) DK369086D0 (el)
ES (1) ES8800888A1 (el)
FI (1) FI863121A (el)
GR (1) GR852895B (el)
HU (1) HU198005B (el)
IL (1) IL77199A (el)
MY (1) MY100972A (el)
NZ (1) NZ214402A (el)
PH (1) PH24502A (el)
PL (1) PL147645B1 (el)
PT (1) PT81603B (el)
WO (1) WO1986003488A1 (el)
ZA (1) ZA859303B (el)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001255A (en) * 1984-12-04 1991-03-19 Sandoz Pharm. Corp. Idene analogs of mevalonolactone and derivatives thereof
EP0221025A1 (en) * 1985-10-25 1987-05-06 Sandoz Ag Heterocyclic analogs of mevalonolactone and derivatives thereof, processes for their production and their use as pharmaceuticals
US4751235A (en) * 1986-12-23 1988-06-14 Sandoz Pharm. Corp. Anti-atherosclerotic indolizine derivatives
US5091378A (en) * 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
US4904691A (en) * 1987-12-21 1990-02-27 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
US4876280A (en) * 1988-03-10 1989-10-24 Sandoz Pharm. Corp. Arylcyclohexane and arylcyclohexene analogs of mevalonolactone derivatives and their use
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
KR0162656B1 (ko) * 1988-10-13 1999-01-15 로쓰 비엠, 하우스 한스-루돌프 7-치환된-헵트-6-엔산 및 -헵탄산과 그의 유도체 및 그의 중간체의 제조방법
FR2642065B1 (fr) * 1989-01-24 1991-05-24 Lipha Derives d'acides benzocycloalcenyl dihydroxy alcanoiques, procede de preparation et medicaments les contenant
US5189180A (en) * 1989-09-28 1993-02-23 E. R. Squibb & Sons, Inc. Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
US5025017A (en) * 1989-09-28 1991-06-18 E. R. Squibb & Sons, Inc. Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
CA2026389A1 (en) * 1989-09-29 1991-03-30 Hideo Nakai Chromene or thiochromene derivatives, process for preparing the same and intermediate therefor
WO1992019239A1 (en) * 1991-05-01 1992-11-12 University Of New Mexico Treatment of aberrant cellular states with biomodulators
WO1992019240A1 (en) * 1991-05-01 1992-11-12 University Of New Mexico Treatment of aberrant cellular states with biomodulators
US5256692A (en) * 1992-01-07 1993-10-26 E. R. Squibb & Sons, Inc. Sulfur-containing HMG-COA reductase inhibitors
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
ES2258141T3 (es) 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
YU31004A (sh) 2001-10-18 2006-08-17 Bristol-Myers Squibb Company Mimetici humanog glukagonu sličnog peptida-1 i njihova upotreba u lečenju dijabetesa i srodnih stanja
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
AU2002348276A1 (en) 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
AU2003225305A1 (en) 2002-05-08 2003-11-11 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
WO2003103632A1 (en) 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
US6995180B2 (en) 2002-10-23 2006-02-07 Bristol Myers Squibb Company Glycinenitrile-based inhibitors of dipeptidyl peptidase IV and methods
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
BR0317521A (pt) 2002-12-20 2005-11-16 Pfizer Prod Inc Formas de dosagem compreendendo um inibidor da cetp e um inibidor da redutase hmg-coa
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
SI1725234T1 (sl) 2004-03-05 2013-04-30 The Trustees Of The University Of Pennsylvania Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076597A1 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006078697A1 (en) 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US7488725B2 (en) 2005-10-31 2009-02-10 Bristol-Myers Squibb Co. Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
CN101820757A (zh) 2007-06-01 2010-09-01 普林斯顿大学托管委员会 通过调节宿主细胞代谢途径治疗病毒感染
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
EP2173717B9 (en) 2007-07-27 2013-06-26 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
RU2443699C2 (ru) 2007-09-20 2012-02-27 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
JP2011503081A (ja) 2007-11-01 2011-01-27 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１および／またはＮＦ−κＢ活性の調節剤として有用な非ステロイド性化合物、並びにその使用
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
BRPI1013500A2 (pt) 2009-03-27 2016-04-05 Astrazeneca Uk Ltd métodos para previnir eventos cardiovasculares adversos maiores com inibidores de dpp-iv
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
US8575168B2 (en) 2009-10-09 2013-11-05 Irm Llc Compounds and compositions as modulators of GPR119 activity
US20120294936A1 (en) 2009-11-13 2012-11-22 Astrazeneca Uk Limited Reduced mass metformin formulations
ES2689107T3 (es) 2009-11-13 2018-11-08 Astrazeneca Ab Formulaciones de tabletas bicapa
JP5784623B2 (ja) 2009-11-13 2015-09-24 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 速放性錠剤製剤
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011130459A1 (en) 2010-04-14 2011-10-20 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
CN107080846A (zh) 2010-07-09 2017-08-22 詹姆斯.特林卡.格林 用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
DK2925735T3 (da) 2012-11-20 2019-06-17 Lexicon Pharmaceuticals Inc Inhibitorer for natriumglucose-cotransporter 1
AR094054A1 (es) * 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
EP3288584A2 (en) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
CA3105626A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
EP3856714A1 (en) 2018-09-26 2021-08-04 Lexicon Pharmaceuticals, Inc. Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
US11535600B2 (en) 2018-12-03 2022-12-27 H. Lundbeck A/S Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5559140A (en) * 1978-10-30 1980-05-02 Sankyo Co Ltd 3,5-dihydroxypentanoic alkyl ester derivative, its preparation and remedy for hyperlipemia containing the same as the effective component
HU204253B (en) * 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US4472426A (en) * 1982-12-22 1984-09-18 Merck & Co., Inc. Antihypercholesterolemic compounds
GR81711B (el) * 1983-01-24 1984-12-12 Sandoz Ag

Also Published As

Publication number Publication date
MY100972A (en) 1991-06-15
AU5230686A (en) 1986-07-01
PL256608A1 (en) 1988-01-07
PH24502A (en) 1990-07-18
PL147645B1 (en) 1989-07-31
FI863121A0 (fi) 1986-07-30
ES549546A0 (es) 1987-12-01
KR870700063A (ko) 1987-02-28
DE3581638D1 (de) 1991-03-07
ATE60571T1 (de) 1991-02-15
EP0216785B1 (en) 1991-01-30
ES8800888A1 (es) 1987-12-01
FI863121A (fi) 1986-07-30
IL77199A (en) 1990-02-09
NZ214402A (en) 1989-01-27
DK369086A (da) 1986-08-01
HU198005B (en) 1989-07-28
AU599580B2 (en) 1990-07-26
WO1986003488A1 (en) 1986-06-19
PT81603B (pt) 1988-04-21
KR910003427B1 (ko) 1991-05-31
PT81603A (en) 1986-01-01
ZA859303B (en) 1987-07-29
HUT40398A (en) 1986-12-28
DK369086D0 (da) 1986-08-01
EP0216785A1 (en) 1987-04-08
JPS62501009A (ja) 1987-04-23

Similar Documents

Publication Publication Date Title
GR852895B (el)
GR851510B (el)
NL950022I1 (el)
ES8604218A1 (es) Un procedimiento para la preparacion de benzoquinolicinas
BR8300242A (pt) Processo para preparacao de fenoxi - fenil - ureias, e, composicoes herbicidas a base das mesmas